Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-1.02 · Revenue $725750.00 · 7 analysts
Est. EPS $-1.01 · Revenue $1.16M · 7 analysts
Est. EPS $-4.15 · Revenue $1.69M · 9 analysts
Est. EPS $-0.97 · Revenue $352000.00 · 2 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $1.5M | -78.6% | +46.7% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-258.8M | -63.9% | +6.6% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +100.0% | +104.5% | +101.8% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -19160.0% | -589.5% | +34.9% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -17253.3% | -667.2% | +36.3% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-213.7M | -33.8% | +9.9% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -14243.9% | -526.1% | +38.6% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 0.4% | -13.2% | +64.1% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 10.49x | -44.6% | +32.5% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $583.0M | -26.4% | +53.0% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -3.90 vs -3.71 | -5.1% | -0.94 vs -1.06 | +11.0% |
| Revenue Surprise | $1.5M vs $2.7M | -44.7% | $22000 vs $734917 | -97.0% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Jun 25, 2026 | Lawver Teri L | officer: SVP & Chief Commercial Officer | Incentive Stock Option (right to buy) | A | 90,000 | $34.09 |
| Jun 25, 2026 | Jimenez Freddy A. | officer: SVP & GENERAL COUNSEL | Incentive Stock Option (right to buy) | A | 93,000 | $34.09 |
| Jun 25, 2026 | Young Diane C. | officer: SVP, CHIEF MEDICAL OFFICER | Incentive Stock Option (right to buy) | A | 57,000 | $34.09 |
| Jun 25, 2026 | Heath-Chiozzi Margo | officer: SVP OF REGULATORY AFFAIRS | Incentive Stock Option (right to buy) | A | 95,000 | $34.09 |
| Jun 25, 2026 | Martin Samuel Bates | officer: SVP AND CFO | Incentive Stock Option (right to buy) | A | 93,000 | $34.09 |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Anthony S. Marucci | Founder, President, Chief Executive Officer & Director | USD 1,339,119 | Male | 1962 | Active |
Tibor Keler | Founder, Chief Scientific Officer & Executive Vice President | USD 867,164 | — | 1959 | Active |
Elizabeth Crowley | Chief Product Development Officer & Senior Vice President | USD 744,058 | Female | 1972 | Active |
Sam Martin | Senior Vice President, Chief Financial Officer, Secretary & Treasurer | USD 739,663 | Male | 1971 | Active |
Margo Heath-Chiozzi | Senior Vice President of Regulatory Affairs | USD 719,484 | — | 1957 | Active |
Diane C. Young | Senior Vice President & Chief Medical Officer | USD 696,453 | — | 1957 | Active |
Freddy A. Jimenez | Senior Vice President & General Counsel | USD 579,698 | Male | 1969 | Active |
Teri L. Lawver | Chief Commercial Officer & Senior Vice President | USD 446,448 | Female | 1967 | Active |
Ronald A. Pepin | Chief Business Officer & Senior Vice President | USD 441,839 | — | 1956 | Active |
Joseph Schlessinger | Co-Founder & Member of Scientific Advisory Board | — | — | 1945 | Active |
Sarah Cavanaugh | Senior Vice President of Corporate Affairs & Administration | — | Female | 1975 | Active |
NEW YORK, Aug. 24, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Celldex Therapeutics, Inc. (NASDAQ: CLDX) on behalf of the company's shareholders. The investigation seeks to determine whether Celldex Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions.
California State Teachers Retirement System raised its holdings in Celldex Therapeutics, Inc. (NASDAQ: CLDX) by 36.4% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The firm owned 79,630 shares of the biopharmaceutical company's stock after buying an additional 21,233 shares during the quarter. California State
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to a loss of $0.85 per share a year ago.
Here is how Celldex Therapeutics (CLDX) and Illumina (ILMN) have performed compared to their sector so far this year.
Celldex Therapeutics (NASDAQ: CLDX) said a Phase 2 trial of barzolvolimab in prurigo nodularis did not meet its primary or secondary endpoints, prompting the company to discontinue development of the drug in that indication while continuing to focus on ongoing late-stage urticaria studies. Anthony Marucci, Celldex's co-founder, president and chief executive officer, said the company was
